دورية أكاديمية
أعرض في EDS

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.

التفاصيل البيبلوغرافية
العنوان: The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
المؤلفون: Wohl, DA1, Bhatti, L2, Small, CB3, Edelstein, H4, Zhao, HH5, Margolis, DA5, DeJesus, E6, Weinberg, WG7, Ross, LL8, Shaefer, MS8
المصدر: HIV Medicine. Feb2016, Vol. 17 Issue 2, p106-117. 12p.
مصطلحات موضوعية: *BIOMARKERS, *HIV, *HIV infections, *HIV-positive persons, *STATISTICAL sampling, *LAMIVUDINE, *DATA analysis software, *ABACAVIR, *ABACAVIR-lamivudine (Drug), *ATAZANAVIR, *DESCRIPTIVE statistics
مستخلص: Objectives HIV treatment guidelines endorse switching or simplification of antiretroviral therapy in therapy-experienced patients with suppressed viraemia; ritonavir discontinuation may also enhance tolerability and reduce long-term adverse events ( AEs). This open-label, multicentre, noninferiority study enrolled HIV-1-infected, treatment-experienced adults with confirmed HIV-1 RNA ≤ 75 HIV-1 RNA copies/mL currently receiving tenofovir/emtricitabine + atazanavir/ritonavir ( TDF/ FTC + ATV/r) for ≥ 6 months with no reported history of virological failure. Methods Participants were randomized 1:2 to continue current treatment or switch to abacavir/lamivudine + atazanavir ( ABC/3TC + ATV). Endpoints included the proportion of participants with HIV-1 RNA < 50 copies/mL by time to loss of virological response ( TLOVR), AEs, fasting lipids, and inflammatory, coagulation, bone and renal biomarkers. Results After 48 weeks, 76% (152 of 199) of ABC/3TC + ATV-treated and 79% (77 of 97) of TDF/ FTC + ATV/r-treated participants had HIV-1 RNA < 50 copies/mL ( TLOVR; P = 0.564). Other efficacy analyses yielded similar results. Rates of new grade 2-4 AEs were 45% in both groups, but an excess of hyperbilirubinaemia made the rate of treatment-emergent grade 3-4 laboratory abnormalities higher with TDF/ FTC + ATV/r (36%) compared with ABC/3TC + ATV (19%). Most fasting lipid levels remained stable over time; high-density lipoprotein ( HDL) cholesterol increased modestly in ABC/3TC + ATV-treated participants. Bone and renal biomarkers improved significantly between baseline and week 48 in participants taking ABC/3TC + ATV and were stable in participants taking TDF/ FTC + ATV/r. No significant changes occurred in any inflammatory or coagulation biomarker within or between treatment groups. Conclusions The ABC/3TC + ATV treatment-switch group had similar viral suppression rates up to 48 weeks to the TDF/ FTC + ATV/r comparator group, with lower rates of moderate- to high-grade hyperbilirubinaemia and improvements in bone and renal biomarkers. [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
ResultId 1
Header asx
Academic Search Index
112463575
1231
6
Academic Journal
academicJournal
1231.0556640625
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=112463575&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:asx&genre=article&issn=14642662&ISBN=&volume=17&issue=2&date=20160201&spage=106&pages=106-117&title=HIV Medicine&atitle=The%20ASSURE%20study%3A%20HIV-1%20suppression%20is%20maintained%20with%20bone%20and%20renal%20biomarker%20improvement%2048%20weeks%20after%20ritonavir%20discontinuation%20and%20randomized%20switch%20to%20abacavir%2Flamivudine%20%2B%20atazanavir.&id=DOI:10.1111/hiv.12281 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Wohl%2C+DA%22&quot;&gt;Wohl, DA&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bhatti%2C+L%22&quot;&gt;Bhatti, L&lt;/searchLink&gt;&lt;relatesTo&gt;2&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Small%2C+CB%22&quot;&gt;Small, CB&lt;/searchLink&gt;&lt;relatesTo&gt;3&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Edelstein%2C+H%22&quot;&gt;Edelstein, H&lt;/searchLink&gt;&lt;relatesTo&gt;4&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Zhao%2C+HH%22&quot;&gt;Zhao, HH&lt;/searchLink&gt;&lt;relatesTo&gt;5&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Margolis%2C+DA%22&quot;&gt;Margolis, DA&lt;/searchLink&gt;&lt;relatesTo&gt;5&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22DeJesus%2C+E%22&quot;&gt;DeJesus, E&lt;/searchLink&gt;&lt;relatesTo&gt;6&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Weinberg%2C+WG%22&quot;&gt;Weinberg, WG&lt;/searchLink&gt;&lt;relatesTo&gt;7&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ross%2C+LL%22&quot;&gt;Ross, LL&lt;/searchLink&gt;&lt;relatesTo&gt;8&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Shaefer%2C+MS%22&quot;&gt;Shaefer, MS&lt;/searchLink&gt;&lt;relatesTo&gt;8&lt;/relatesTo&gt; )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22HIV+Medicine%22&quot;&gt;HIV Medicine&lt;/searchLink&gt;. Feb2016, Vol. 17 Issue 2, p106-117. 12p. )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => *&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22BIOMARKERS%22&quot;&gt;BIOMARKERS&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22HIV%22&quot;&gt;HIV&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22HIV+infections%22&quot;&gt;HIV infections&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22HIV-positive+persons%22&quot;&gt;HIV-positive persons&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22STATISTICAL+sampling%22&quot;&gt;STATISTICAL sampling&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22LAMIVUDINE%22&quot;&gt;LAMIVUDINE&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22DATA+analysis+software%22&quot;&gt;DATA analysis software&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ABACAVIR%22&quot;&gt;ABACAVIR&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ABACAVIR-lamivudine+%28Drug%29%22&quot;&gt;ABACAVIR-lamivudine (Drug)&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ATAZANAVIR%22&quot;&gt;ATAZANAVIR&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22DESCRIPTIVE+statistics%22&quot;&gt;DESCRIPTIVE statistics&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Objectives HIV treatment guidelines endorse switching or simplification of antiretroviral therapy in therapy-experienced patients with suppressed viraemia; ritonavir discontinuation may also enhance tolerability and reduce long-term adverse events ( AEs). This open-label, multicentre, noninferiority study enrolled HIV-1-infected, treatment-experienced adults with confirmed HIV-1 RNA ≤ 75 HIV-1 RNA copies/mL currently receiving tenofovir/emtricitabine + atazanavir/ritonavir ( TDF/ FTC + ATV/r) for ≥ 6 months with no reported history of virological failure. Methods Participants were randomized 1:2 to continue current treatment or switch to abacavir/lamivudine + atazanavir ( ABC/3TC + ATV). Endpoints included the proportion of participants with HIV-1 RNA &lt; 50 copies/mL by time to loss of virological response ( TLOVR), AEs, fasting lipids, and inflammatory, coagulation, bone and renal biomarkers. Results After 48 weeks, 76% (152 of 199) of ABC/3TC + ATV-treated and 79% (77 of 97) of TDF/ FTC + ATV/r-treated participants had HIV-1 RNA &lt; 50 copies/mL ( TLOVR; P = 0.564). Other efficacy analyses yielded similar results. Rates of new grade 2-4 AEs were 45% in both groups, but an excess of hyperbilirubinaemia made the rate of treatment-emergent grade 3-4 laboratory abnormalities higher with TDF/ FTC + ATV/r (36%) compared with ABC/3TC + ATV (19%). Most fasting lipid levels remained stable over time; high-density lipoprotein ( HDL) cholesterol increased modestly in ABC/3TC + ATV-treated participants. Bone and renal biomarkers improved significantly between baseline and week 48 in participants taking ABC/3TC + ATV and were stable in participants taking TDF/ FTC + ATV/r. No significant changes occurred in any inflammatory or coagulation biomarker within or between treatment groups. Conclusions The ABC/3TC + ATV treatment-switch group had similar viral suppression rates up to 48 weeks to the TDF/ FTC + ATV/r comparator group, with lower rates of moderate- to high-grade hyperbilirubinaemia and improvements in bone and renal biomarkers. [ABSTRACT FROM AUTHOR] )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1111/hiv.12281 ) ) [Languages] => Array ( [0] => Array ( [Code] => eng [Text] => English ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 12 [StartPage] => 106 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => BIOMARKERS [Type] => general ) [1] => Array ( [SubjectFull] => HIV [Type] => general ) [2] => Array ( [SubjectFull] => HIV infections [Type] => general ) [3] => Array ( [SubjectFull] => HIV-positive persons [Type] => general ) [4] => Array ( [SubjectFull] => STATISTICAL sampling [Type] => general ) [5] => Array ( [SubjectFull] => LAMIVUDINE [Type] => general ) [6] => Array ( [SubjectFull] => DATA analysis software [Type] => general ) [7] => Array ( [SubjectFull] => ABACAVIR [Type] => general ) [8] => Array ( [SubjectFull] => ABACAVIR-lamivudine (Drug) [Type] => general ) [9] => Array ( [SubjectFull] => ATAZANAVIR [Type] => general ) [10] => Array ( [SubjectFull] => DESCRIPTIVE statistics [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Wohl, DA ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bhatti, L ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Small, CB ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Edelstein, H ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Zhao, HH ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Margolis, DA ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => DeJesus, E ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Weinberg, WG ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Ross, LL ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shaefer, MS ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 02 [Text] => Feb2016 [Type] => published [Y] => 2016 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 14642662 ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 17 ) [1] => Array ( [Type] => issue [Value] => 2 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => HIV Medicine [Type] => main ) ) ) ) ) ) )
IllustrationInfo